新浪登录
腾讯登录阿斯利康与哈佛联合开展糖尿病细胞疗法
| 导读 | 阿斯利康将开展为期五年的研究项目，利用美国哈佛大学干细胞技术发现新的糖尿病治疗手段。 |
阿斯利康将开展为期五年的研究项目，利用美国哈佛大学干细胞技术发现新的糖尿病治疗手段。
合作双方打算开发适合将干细胞转化为人类β细胞的细胞治疗技术，β细胞是胰腺的胰岛素生产细胞，可以作为用于治疗糖尿病的新型药物。
阿斯利康公司在声明中表示，哈佛大学的相关工作克服了现阶段学界糖尿病研究的一个关键性瓶颈，人类β细胞水平与糖尿病有着极大的相关性。
阿斯利康公司已经毫不掩饰其在糖尿病领域的野心——该公司相信国际糖尿病市场在近几年将继续强劲增长,尽管与其竞争对手的竞争日益激烈，价格压力日益上升,与哈佛干细胞研究所(HSCI)的业务合作仍处在征程之上。
与HSCI的合作将拓展阿斯利康由联合主席道格·梅尔顿教授所领导的研究性工作，极大数量的人类β细胞可以由人类诱导多能干细胞分化并用于治疗糖尿病。
去年十月，梅尔顿教授与其合作者将相关的细胞治疗技术成果发表在了《细胞》杂志上意味着其为期15年的研究正走向高潮，使得应用β细胞创建人工胰腺解决糖尿病患者胰岛素给药问题成为可能。
研究团队已经将β细胞植入糖尿病小鼠,并发现这些小鼠某种程度的胰岛素功能在给药后得到了恢复。（转化医学网360zhyx.com）
以上为转化医学网原创翻译整理，如需转载，请联系 info@360zhyx.com 。转化医学网推荐的新闻阅读：
The two partners intend to adapt a technique that converts stem cells into human beta cells - the insulin-producing cells in the pancreas - so they can be used to screen AZ's compound library for new diabetes leads.
Harvard's work overcomes a key bottleneck in diabetes research, as human beta cells for research purposes "are extremely limited in number and availability," said AZ in a statement.
The company has made no secret of its ambitions in diabetes - the company is confident the market will continue to grow strongly despite reports of increasing competition and pricing pressure among its rivals in the category - and the deal with the Harvard Stem Cell Institute (HSCI) indicates it is in it for the long-haul.
The collaboration with HSCI will extend the work of researchers led by the unit's co-chairman - Professor Doug Melton - which allows "limitless quantities" of beta cells to be produced from human induced pluripotent stem cells (IPSCs) generated directly from adult cells.
Last October, Melton and his co-workers published the technique in the journal Cell, marking the culmination of 15 years of research, sparking speculation that the beta cells could be used to create an artificial pancreas that - one day - could end diabetics' reliance on insulin injections.
The team have implanted the cells into diabetic mice and found that they restored some degree of insulin function.
合作双方打算开发适合将干细胞转化为人类β细胞的细胞治疗技术，β细胞是胰腺的胰岛素生产细胞，可以作为用于治疗糖尿病的新型药物。
阿斯利康公司在声明中表示，哈佛大学的相关工作克服了现阶段学界糖尿病研究的一个关键性瓶颈，人类β细胞水平与糖尿病有着极大的相关性。
阿斯利康公司已经毫不掩饰其在糖尿病领域的野心——该公司相信国际糖尿病市场在近几年将继续强劲增长,尽管与其竞争对手的竞争日益激烈，价格压力日益上升,与哈佛干细胞研究所(HSCI)的业务合作仍处在征程之上。
与HSCI的合作将拓展阿斯利康由联合主席道格·梅尔顿教授所领导的研究性工作，极大数量的人类β细胞可以由人类诱导多能干细胞分化并用于治疗糖尿病。
去年十月，梅尔顿教授与其合作者将相关的细胞治疗技术成果发表在了《细胞》杂志上意味着其为期15年的研究正走向高潮，使得应用β细胞创建人工胰腺解决糖尿病患者胰岛素给药问题成为可能。
研究团队已经将β细胞植入糖尿病小鼠,并发现这些小鼠某种程度的胰岛素功能在给药后得到了恢复。（转化医学网360zhyx.com）
以上为转化医学网原创翻译整理，如需转载，请联系 info@360zhyx.com 。转化医学网推荐的新闻阅读：
The two partners intend to adapt a technique that converts stem cells into human beta cells - the insulin-producing cells in the pancreas - so they can be used to screen AZ's compound library for new diabetes leads.
Harvard's work overcomes a key bottleneck in diabetes research, as human beta cells for research purposes "are extremely limited in number and availability," said AZ in a statement.
The company has made no secret of its ambitions in diabetes - the company is confident the market will continue to grow strongly despite reports of increasing competition and pricing pressure among its rivals in the category - and the deal with the Harvard Stem Cell Institute (HSCI) indicates it is in it for the long-haul.
The collaboration with HSCI will extend the work of researchers led by the unit's co-chairman - Professor Doug Melton - which allows "limitless quantities" of beta cells to be produced from human induced pluripotent stem cells (IPSCs) generated directly from adult cells.
Last October, Melton and his co-workers published the technique in the journal Cell, marking the culmination of 15 years of research, sparking speculation that the beta cells could be used to create an artificial pancreas that - one day - could end diabetics' reliance on insulin injections.
The team have implanted the cells into diabetic mice and found that they restored some degree of insulin function.
还没有人评论，赶快抢个沙发